<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015426</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20305</org_study_id>
    <nct_id>NCT05015426</nct_id>
  </id_info>
  <brief_title>Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT</brief_title>
  <official_title>Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Florida Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness&#xD;
      of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single&#xD;
      infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with&#xD;
      Acute Myeloid Leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Maximum Tolerated Dose will be determined by testing increasing doses of AAPC-expanded donor γδ T-cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Leukemia Free Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Leukemia-free survival is defined as the time from the date of start of treatment to the date of relapse of AML or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Graft Versus Host Disease (GVHD)</measure>
    <time_frame>at 6 weeks</time_frame>
    <description>Number of participants with grade II-IV and III-IV acute GVHD within 6 weeks after infusion of Gamma T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The length of time from start of treatment to death by any cause.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level -1 may be used as a de-escalation dose level due to Dose Limiting Toxicities (DLTs) from Dose Level 1&#xD;
Participants will receive 1.0 x 106 cells/kg (0.75-1.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5.0 x 106 cells/kg (3.75-6.25 x 106 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2.5 x 107 cells/kg (1.875-3.125 x 107 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1.0 x 108 cells/kg (0.75-1.25 x 108 cells/kg) Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment at Maximum Tolerated Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells at the dose determined to be the Maximum Tolerated Dose, administered as a single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gamma Delta T-Cell Infusion</intervention_name>
    <description>Donor cells will be processed in a laboratory, where T-cell subtype called γδ (gamma delta) T-cells will be isolated and expanded in number. These T-cells expanded in a laboratory will be infused in participants who are otherwise at high risk of AML recurrence after alloHCT.</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Treatment at Maximum Tolerated Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged between 18 and 75 years of age undergoing allogeneic&#xD;
             hematopoietic stem cell transplantation (alloHCT) or the treatment of Acute Myeloid&#xD;
             Leukemia (AML) with detectable minimal residual disease (MRD) either before or after&#xD;
             alloHCT&#xD;
&#xD;
          -  Have &lt; 5% blasts in bone marrow by morphology at the time of transplantation but&#xD;
             pre-alloHCT flow cytometric or molecular evidence of MRD&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥ 70% during the study screening.&#xD;
&#xD;
          -  Free of symptomatic congestive heart failure or uncontrolled arrhythmia&#xD;
&#xD;
          -  Adequate organ function as defined per protocol&#xD;
&#xD;
          -  Negative serum pregnancy test&#xD;
&#xD;
          -  Note: Women of child-bearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control or abstinence) prior to&#xD;
             study entry and for at least 30 days following study treatment (T-cell infusion);&#xD;
             should a woman subject or female partner of a male subject become pregnant or suspect&#xD;
             that she is pregnant while participating on the trial, she should inform her treating&#xD;
             physician immediately.&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Agreement to adhere to Lifestyle Considerations throughout study duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of concomitant systemic glucocorticoid for any reason will not be allowed&#xD;
             in order to avoid their immunosuppressive effects on γδ T-cell function.&#xD;
&#xD;
          -  Active grade II-IV acute GVHD (patients with prior GVHD should be off prednisone for&#xD;
             at least 14 days prior to infusion of the study cell product).&#xD;
&#xD;
          -  Uncontrolled serious infection.&#xD;
&#xD;
          -  Morphologic relapse of leukemia at any timepoint after HCT.&#xD;
&#xD;
          -  Active central nervous system malignancy.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Treatment with another investigational drug or other intervention within 14 days of&#xD;
             T-cell infusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelli Bejanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Davila, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Blanton</last_name>
      <phone>813-745-4285</phone>
      <email>Rachel.Blanton@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Alsina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hany Elmariah, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rawan Faramand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Lancet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandr Lazaryan, MD, MPH, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hien Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Locke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asmita Mishra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Nieder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiga Nishihori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ochoa-Bayona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lia Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Pidala, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

